This article is more than 5 years old. Information may no longer be current.
Continuous glucose monitoring system receives FDA approval
Click Here to Manage Email Alerts
The FDA has approved Medtronic’s iPro2, a next-generation professional continuous glucose monitoring system.
The 3-day evaluation system is designed to make continuous glucose monitoring easy for health care professionals and patients to use, according to a press release. It can be used to identify nocturnal hypoglycemia or postprandial hyperglycemia.
The setup procedure is a three-step process enabled by a new “smart” dock, which reduces the number of required components and eliminates the need for a computer. Setup can be completed in a few minutes and includes inserting a glucose sensor into the patient’s skin, educating the patient and connecting the system to the sensor, according to the press release. The patient then performs normal daily activities while the system records and stores as many as 288 glucose readings during each 24-hour period. After 3 days of wear, the patient returns the system for upload to Web-based software, which provides a summary of glucose data. Patient data and software are accessible by any computer with an Internet connection.
The reports can be used to motivate patients to implement changes in their diabetes management based on the effects that food, exercise, stress, medications or other activities have on glucose levels.
 |
Follow EndocrineToday.com on Twitter. |